Yaupon Therapeutics Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Published: Jul 28, 2011
MALVERN, Pa.--(BUSINESS WIRE)--Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine). Yaupon is seeking U.S. marketing approval of its mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). Yaupon’s formulation is a water-soluble, greaseless topical gel.